Accelerate Diagnostics

Accelerate Diagnostics Goodwill/Assets

Delisted

The Goodwill to Total Assets Ratio of Accelerate Diagnostics (AXDX) as of Nov 10, 2026 is 0.06 %. In the previous year, Goodwill to Total Assets Ratio was 0.11 % — a change of -41.81% (lower).

Goodwill/Assets

0.06 %

YoY

-41.81%

Last updated:

Goodwill to Total Assets Ratio of Accelerate Diagnostics is 2018 0.06 % . Goodwill to Total Assets Ratio of Accelerate Diagnostics was 2017 0.11 % . It decreases by -41.81% lower compared to the previous year.

The Accelerate Diagnostics Goodwill/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Goodwill/Assets
Date
Goodwill/Assets
Jan 1, 2014
0.24 USD
Jan 1, 2015
0.11 USD
Jan 1, 2016
0.18 USD
Jan 1, 2017
0.11 USD
Jan 1, 2018
0.06 USD
The Accelerate Diagnostics Goodwill/Assets history
YEARGoodwill/AssetsYoY
0.06 %-41.81%
0.11 %-40.00%
0.18 %+56.38%
0.11 %-52.90%
0.24 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Accelerate Diagnostics Stock analysis

What does Accelerate Diagnostics do? Accelerate Diagnostics, Inc. generates revenue through its Accelerate Pheno system, an in vitro diagnostic platform that combines genotypic pathogen identification with phenotypic antibiotic susceptibility testing. The company sells the Accelerate Pheno system, including the fixed instrument and single-use test kits, to healthcare facilities for rapid diagnosis of serious infections. The Accelerate PhenoTest BC Kit specifically targets bacteremia and fungemia cases, providing ID and AST results directly from patient samples. Healthcare providers, particularly those treating life-threatening infections with high mortality risks, purchase these solutions to improve patient outcomes and reduce healthcare costs. The Accelerate Pheno system's walk-away automation feature reduces manual labor in laboratories, appealing to hospitals and clinical labs seeking efficiency. The company's focus on rapid diagnosis of serious infections aligns with healthcare institutions' needs for faster treatment decisions. By offering direct pathogen identification followed by targeted antibiotic testing, the system helps clinicians choose effective treatments more quickly, addressing high morbidity and mortality risks associated with bloodstream infections. Accelerate Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Accelerate Diagnostics stock

Goodwill to Total Assets Ratio of Accelerate Diagnostics is 0.06 % in 2018.

Goodwill to Total Assets Ratio of Accelerate Diagnostics changed from 0.11 % to 0.06 %, representing a -41.81% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Goodwill to Total Assets Ratio Accelerate Diagnostics since 2006 – with annual values, charts, and detailed analysis.

The Goodwill/Assets ratio shows what percentage of total assets consists of acquisition goodwill. High ratios may indicate impairment risk.

Goodwill to Total Assets Ratio's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill to Total Assets Ratio's Accelerate Diagnostics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Accelerate Diagnostics

All Key Metrics — Accelerate Diagnostics